SAN DIEGO – Data from Genentech Inc.’s 1,202-patient Phase III GALLIUM clinical trial in previously untreated follicular lymphoma showed a 34% reduction in the risk of disease progression or death for the Roche subsidiary’s Gazyva (obinutuzumab) compared with the company’s own Rituxan (rituximab) – a result that investigators view as potentially practice-changing.
GALLIUM investigator Robert Marcus, a hematologist at Kings College Hospital in London, said the progression-free survival (PFS) for follicular lymphoma patients enrolled in the study shows that Gazyva in combination with chemotherapy is “markedly superior” to Rituxan plus chemotherapy, which is the standard of care in the first-line induction and maintenance therapy setting
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?